New Technology to Transform Cancer Diagnostics and Treatment

1000 patients can now be tested for cancer using an innovative non-invasive technology known as Electric Field-Induced Release and Measurement (EFIRM) liquid Biopsy within a day.

This was revealed during the launch of the machine at the KAVI Institute of Clinical Research at the University’s College of Health Sciences on Friday July 19, 2019.

During the Commissioning, the Chancellor, Dr. Vijoo Rattansi expressed her delight at the innovation from EZLIFE Biotechnology firm that has made this possible through the University’s partnership with Cherami Africa Group. “I am glad that all Kenyans can afford cancer screening through this innovation; even poor kenyans who cannot afford to pay for the tests, can now get tested. This is why we are here as a University to serve the society.”

On his part, the Vice Chancellor, Prof. Isaac M. Mbeche congratulated the team that spearheaded the research at KAVI and pledged to support them in achieving their mandate.

Prof. Mbeche noted how the two Directors Dr. Liao Wei and Dr. Fang Wei (Mrs)  who have brought about the innovation are philanthropist and they are not after money. “Kenyans are really feeling the effects of cancer, many of our relatives are dying. If we establish the cancer institute, it will help many Kenyans.”

 

Deputy Vice Chancellor, Academic Affairs, Prof. Julius Ogeng’o commended the success of the Clinical Institute for their accomplishment, He said, “ KAVI will grow from one generation to another,  Liquid biopsy will transform the diagnosis of cancer while Contributing to Universal Health Coverage.”

 This is ‘early- harvesting’ of the partnership that the University signed with Cherami Africa Group for establishment of a cancer institute in November 2018 before the hospital is built.

KAVI Institute of Clinical Research will soon publish a date for the official launch when the liquid biopsy machine will take its first test for the public.  

Expiry Date: 
Fri, 2022-04-01 (All day)